Biography

Dr Di Leva joined the Institute for Science & Technology in Medicine at Keele University as a Senior Lecturer in April 2019. He studied Pharmaceutical Sciences at the University of Rome “La Sapienza” working on noncoding RNA and its multiple functions and extraordinary plasticity. He graduated cum laude in 2004 and with the support of the Italia-USA Program Fellowship, Gianpiero moved as a predoctoral student first to the Kimmel Cancer Centre in Philadelphia and then to Ohio State University where he completed in 2009 his PhD, based both at University of Ferrara and Ohio State University. During this time, he acquired an interest in the role of small non-coding RNAs and their involvement in cancer by showing how they re-programme gene expression to confer proliferative advantage to cancer cells and induce resistance to therapeutic agents. In 2014, he decided to move with his family to Manchester where he joined the Cancer Research UK-Manchester Institute and had the opportunity to work in drug discovery for the development of new drugs targeting cancer stem cells.

In December 2015, he became lecturer in biomedical sciences and started his first independent laboratory at Salford University. In 2019, his laboratory relocated to Keele University with the aim to identify vulnerabilities in cancer cells and define innovative way to target them.

Research and scholarship

Dr Di Leva research focuses on his long-standing interest in exploring the molecular roles of non-coding RNAs in determining cell fate changes and gene regulation. “I really believe that discovering how non-coding RNAs regulate gene expression will improve our understanding of development and disease and it will allow the development of novel therapeutic strategies”. For more information please visit our laboratory website at https://dilevalab.wordpress.com

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep. 2017; 7(1): 3140.

Tang HR, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer CJ and Marais R. Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nature Communications. 2017; 8:14909.

Di Leva G, Garofalo M, Croce CM. microRNA in cancer. Annu Rev Pathol. 2014; 9:287-314.

Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DC, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Ramasamy S, Marcucci G, Perrotti D, Powell KA, Brasatz A, Garofalo M, Nephew KP, and Croce CM. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on Estrogen Receptor status. PloS Genetics. 2013; 9:e1003311.

Garofalo M*, Romano G*, Di Leva G*, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli M, Jeffrey A Engelman, Mayumi Ono, Jin Kyung Rho, Volinia S, Nephew KP, Croce CM. EGFR and MET receptor tyrosine kinases induce tumorigenesis and gefitinib resistance in lung cancer by controlling microRNA expression. Nature Medicine. 2010;18:74-82.
*these authors contributed equally to this work.

Rao X, Di Leva G, Li M, Fang F, Hartman-Frey C, Burow ME, Croce CM, and Nephew KP. MicroRNA-221/222 cluster confers breast cancer fulvestrant resistance by regulating multiple pathway activities. Oncogene. 2010; 30:1082-97.

Di Leva G, and Croce CM. Role of microRNAs in tumor formation. Trends in Molecular Medicine. 2010; 16:257-67.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli T, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM. 2010, MicroRNA cluster 221/222 and estrogen receptor alpha interactions in breast cancer. Journal of National Cancer Institute. 2010; 102:706-21.

Garofalo M, Di Leva G, Romano G, Nuovo G, Sung SS, Ngankeu A, Taccioli C, Secchiero P, Alder H, Gasparini P, Costinean S, Acunzo M, Condorelli G and Croce CM. miR221&222 enhance tumorigenesis and induce TRAIL resistance by enhancing PTEN and TIMPP3 tumor-suppressors. Cancer Cell. 2009; 16:498-509.

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New England Journal of Medicine. 2005; 353:1793-801.

Selected Publications

  • Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM. 2013. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genetics, vol. 9(3), e1003311. link> doi> full text>
  • Di Leva G and Croce CM. 2013. miRNA profiling of cancer. Curr Opin Genet Dev, vol. 23(1), 3-11. link> doi>
  • Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong H-S, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M. 2020. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Mol Med, vol. 12(7), e11099. link> doi> full text>
  • Tang H, Leung L, Saturno G, Viros A, Smith D, Leva GD, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R. 2019. Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nat Commun, vol. 10(1), 3151. link> doi>
  • Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook WJJ, Di Leva G, d'Adamo AP, Gasparini P, Volinia S. 2019. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers (Basel), vol. 11(4). link> doi> full text>

Full Publications List show

Journal Articles

  • Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong H-S, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M. 2020. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Mol Med, vol. 12(7), e11099. link> doi> full text>
  • Tang H, Leung L, Saturno G, Viros A, Smith D, Leva GD, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R. 2019. Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nat Commun, vol. 10(1), 3151. link> doi>
  • Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook WJJ, Di Leva G, d'Adamo AP, Gasparini P, Volinia S. 2019. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers (Basel), vol. 11(4). link> doi> full text>
  • Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, Gardiman MP, Sacchi D, Calore F, Carosi M, Antenucci A, Casini B, Kelani H, Pescarmona E, Di Leva G, Zanesi N, Berger MS, Croce CM. 2018. Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. EBioMedicine, vol. 30, 105-112. link> doi> full text>
  • Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C, Baldassari F, Fassan M, Bartolazzi A, Vecchione A, Nuovo GJ, Di Leva G, D'Atri S, Alvino E, Previati M, Nickoloff BJ, Croce CM, Volinia S. 2018. Loss of miR-204 expression is a key event in melanoma. Molecular Cancer, vol. 17(1), 71. link> doi> full text>
  • Cheung DG, Buzzetti M, Di Leva G. 2017. miRNAs in bone metastasis. Expert Rev Endocrinol Metab, vol. 12(6), 451-461. link> doi> full text>
  • De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S. 2017. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Scientific Reports, vol. 7(1), 3140. link> doi> full text>
  • Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R. 2017. Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nature Communications, vol. 8, 14909. link> doi> full text>
  • D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV. 2016. miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Res, vol. 76(18), 5562-5572. link> doi>
  • Taccioli C, Garofalo M, Chen H, Jiang Y, Tagliazucchi GM, Di Leva G, Alder H, Fadda P, Middleton J, Smalley KJ, Selmi T, Naidu S, Farber JL, Croce CM, Fong LY. 2015. Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo. J Natl Cancer Inst, vol. 107(11). link> doi>
  • Jeon Y-J, Middleton J, Kim T, Laganà A, Piovan C, Secchiero P, Nuovo GJ, Cui R, Joshi P, Romano G, Di Leva G, Lee B-K, Sun H-L, Kim Y, Fadda P, Alder H, Garofalo M, Croce CM. 2015. A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A, vol. 112(26), E3355-E3364. link> doi> full text>
  • Garofalo M, Jeon Y-J, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM. 2015. Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One, vol. 10(6), e0131729. link> doi>
  • Di Leva G, Cheung DG, Croce CM. 2015. miRNA clusters as therapeutic targets for hormone-resistant breast cancer. Expert Rev Endocrinol Metab, vol. 10(6), 607-617. link> doi>
  • Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R. 2014. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst, vol. 106(12). link> doi>
  • Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Garzon R, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corra F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM. 2014. Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer (vol 106, dju324, 2014). JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 106(11). link> doi>
  • Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM. 2014. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation (vol 109, pg 16570, 2012). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 111(28), 10389. link> doi>
  • Drusco A, Nuovo GJ, Zanesi N, Di Leva G, Pichiorri F, Volinia S, Fernandez C, Antenucci A, Costinean S, Bottoni A, Rosito IA, Liu C-G, Burch A, Acunzo M, Pekarsky Y, Alder H, Ciardi A, Croce CM. 2014. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One, vol. 9(6), e96670. link> doi>
  • Garofalo M, Leva GD, Croce CM. 2014. MicroRNAs as anti-cancer therapy. Curr Pharm Des, vol. 20(33), 5328-5335. link> doi>
  • Di Leva G, Garofalo M, Croce CM. 2014. MicroRNAs in cancer. Annu Rev Pathol, vol. 9, 287-314. link> doi>
  • Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, Nuovo A, Magro CM, Di Leva G, Nuovo GJ. 2013. Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Mod Pathol, vol. 27(6), 851-862. link> doi> full text>
  • Di Leva G and Croce CM. 2013. MicroRNAs. Clin Biochem, vol. 46(10-11), 840-841. link> doi>
  • Garofalo M, Jeon Y-J, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM. 2013. MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One, vol. 8(6), e67581. link> doi> full text>
  • Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP, Croce CM. 2013. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genetics, vol. 9(3), e1003311. link> doi> full text>
  • Di Leva G and Croce CM. 2013. miRNA profiling of cancer. Curr Opin Genet Dev, vol. 23(1), 3-11. link> doi>
  • Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM. 2012. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A, vol. 109(41), 16570-16575. link> doi>
  • Di Leva G, Briskin D, Croce CM. 2012. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci, vol. 117(2), 202-216. link> doi>
  • Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM. 2012. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Molecular Oncology, vol. 6(4), 458-472. link> doi> full text>
  • Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. 2011. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med, vol. 18(1), 74-82. link> doi>
  • Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP. 2011. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene, vol. 30(9), 1082-1097. link> doi>
  • Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin H-J, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM. 2010. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, vol. 18(4), 367-381. link> doi>
  • Nuovo GJ, Wu X, Volinia S, Yan F, di Leva G, Chin N, Nicol AF, Jiang J, Otterson G, Schmittgen TD, Croce C. 2010. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn Mol Pathol, vol. 19(3), 135-143. link> doi>
  • Di Leva G and Croce CM. 2010. Roles of small RNAs in tumor formation. Trends Mol Med, vol. 16(6), 257-267. link> doi>
  • Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM. 2010. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst, vol. 102(10), 706-721. link> doi>
  • Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia M-A, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu C-G, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. 2010. Reprogramming of miRNA networks in cancer and leukemia. Genome Res, vol. 20(5), 589-599. link> doi>
  • Garofalo M, Di Leva G, Romano G, Nuovo G, Suh S-S, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM. 2009. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, vol. 16(6), 498-509. link> doi>
  • Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S. 2009. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol, vol. 35(2), 393-400. link> doi>
  • Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. 2009. microRNA-205 regulates HER3 in human breast cancer. Cancer Res, vol. 69(6), 2195-2200. link> doi>
  • Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. 2008. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, vol. 27(27), 3845-3855. link> doi>
  • Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM. 2008. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem, vol. 283(20), 13736-13744. link> doi>
  • Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu C-G, Alder H, Calin GA, Ménard S, Croce CM. 2007. MicroRNA signatures in human ovarian cancer. Cancer Res, vol. 67(18), 8699-8707. link> doi>
  • Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM. 2006. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. CANCER RESEARCH, vol. 66(21), 10287-10291. link> doi>
  • Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM. 2006. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res, vol. 66(21), 10287-10291. link> doi>
  • Di Leva G, Calin GA, Croce CM. 2006. MicroRNAs: fundamental facts and involvement in human diseases. Birth Defects Res C Embryo Today, vol. 78(2), 180-189. link> doi>
  • Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu C-G, Kipps TJ, Negrini M, Croce CM. 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, vol. 353(17), 1793-1801. link> doi>
  • de Turris V, Di Leva G, Caldarola S, Loreni F, Amaldi F, Bozzoni I. 2004. TOP promoter elements control the relative ratio of intron-encoded snoRNA versus spliced mRNA biosynthesis. J Mol Biol, vol. 344(2), 383-394. link> doi>
  • Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, Sellers R, Brullé-Soumaré L, Cairo S, Monteverde T, Volinia S, Smith DD, Di Leva G, Galuppini F, Paliouras AR, Zeng K, O'Keefe RT, Garofalo M. A KRAS-responsive long non-coding RNA controls microRNA processing. full text>
  • Diala I, Shiohama Y, Fujita T, Kotake Y, Demonacos C, Krstic-Demonacos M, Leva GD, Fujii M. 2020. Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT. Nucleosides Nucleotides Nucleic Acids, vol. 39(1-3), 407-425. link> doi> full text>

Other

  • Cheung DG, Buzzetti M, Croce CM, di Leva G. 2018. CDK inhibitor PHA-848125 preferentially inhibits proliferation of triple negative breast cancer and synergizes with cisplatin. CANCER RESEARCH (vol. 78). link> doi>
  • Di Leva G, Piovan C, Cheung D, Briskin D, Kumar A, Nuovo G, Fassan M, Coppola V, Garofalo M, Croce C. 2013. miR-222/221 in aggressive breast cancer. MOLECULAR CANCER RESEARCH (vol. 11). link> doi>
  • Jeon Y-J, Nuovo GJ, Midddleton J, Joshi P, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Garofalo M, Croce CM. 2013. MiR-34a/c-dependent PDGFR-alpha/beta reduction inhibits tumorigenesis and sensitizes TRAIL-induced apoptosis in lung cancer. CANCER RESEARCH (vol. 73). link> doi>
  • Taccioli C, Chen H, Garofalo M, Jiang Y, Di Leva G, Alder H, Middleton J, Smalley KJ, Bottoni A, Costinean S, Farber JL, Croce CM, Fong LYY. 2013. Silencing of microRNA-31 prevents esophageal neoplasia in zinc deficient rats. CANCER RESEARCH (vol. 73). link> doi>
  • Iorio M, Piovan C, Di Leva G, Palmieri D, Casalini P, Braccioli L, Tortoreto M, Taccioli C, Croce C, Tagliabue E. 2011. Breast cancer and microRNAs: Therapeutic impact. BREAST (vol. 20, p. S6). link> doi>
  • Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu JR, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. 2010. Reprogramming of miRNA networks in cancer and leukemia. EUROPEAN JOURNAL OF MEDICAL RESEARCH (vol. 15, p. 152). link>
  • Iorio MV, Piovan C, Di Leva G, Casalini P, Tortoreto M, Plantamura I, Taccioli C, Croce CM, Tagliabue E. 2010. MiR-205 role in triple negative breast cancer. CANCER RESEARCH (vol. 70). link> doi>
  • Rao X, Di Leva G, Li M, Fang F, Balch C, Thomson J, Hammond S, Hartman-Frey C, Liu Y, Croce C, Nephew K. 2009. MicroRNA-221/222 confer breast cancer resistance to fulvestrant by targeting multiple oncogenic activities. CANCER RESEARCH (vol. 69). link>
  • Di Leva G, Ngankeu A, Gasparini P, Li M, Taccioli C, Garofalo M, Iorio M, Piovan C, Nephew K, Croce C. 2009. miR191 reprogrames gene expression to control invasiveness of breast cancer. CANCER RESEARCH (vol. 69). link>
  • Lorio M, Piovan C, Casalini P, Di Leva G, Merlo A, Triulzi T, Menard S, Croce C, Tagliabue E. 2009. miR-205: A new tumor suppressor in breast cancer. CANCER RESEARCH (vol. 69). link>
  • Garofalo M, Di Leva G, Romano G, Ngankeu A, Suh S-S, Alder H, Costinean S, Acunzo M, Nuovo G, Pekarsky Y, Condorelli G, Croce C. 2009. MiR-221&222 enhance migration and invasiveness of NSCLC and hepatocarcinoma cells by targeting PTEN tumor suppressor. CANCER RESEARCH (vol. 69). link>
  • Mascellani N, Tagliavini L, Gamberoni G, Rossi S, Marchesini J, Taccioli C, Di Leva G, Negrini M, Croce C, Volinia S. 2008. Using miRNA expression data for the study of human cancer. MINERVA BIOTECNOLOGICA (vol. 20, pp. 23-30). link>
Top 10 CUG Top 5 Guardian Athena SWAN